A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics

Carla Casulo, Julie Marie Vose, William Y. Ho, Brad Kahl, Mark Brunvand, Andre Goy, Yvette Kasamon, Bruce Cheson, Jonathan W. Friedberg

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

PRO131921 is a third-generation, humanized anti-CD20 monoclonal antibody with increased antibody-dependent cytotoxicity and complement-dependent cytotoxicity compared to rituximab. In this phase I study, PRO131921 was administered as a single agent to patients with CD20+, relapsed or refractory, indolent non-Hodgkin lymphoma (NHL) who had been treated with a prior rituximab-containing regimen. The primary aim of this study was safety and tolerability of PRO131921. The secondary aim of the study, and focus of this report, was to determine the pharmacokinetics (PK) profile of PRO131921 and establish a correlation between drug exposure and clinical efficacy. Patients were treated with PRO131921 by intravenous infusion weekly for 4weeks and the dose was escalated based on safety in a 3+3 design. Twenty-four patients were treated with PRO131921 at doses from 25mg/m2 to 800mg/m2. Analysis of PK data demonstrated a correlation between higher normalized drug exposure (normalized AUC) and tumor shrinkage (p=0035). Also, normalized AUC levels were higher among responders and subjects displaying tumor shrinkage versus subjects progressing or showing no regression (p=0.030). In conclusion, PRO131921 demonstrated clinical activity in rituximab-relapsed and refractory indolent NHL patients. The observation that higher normalized AUC may be associated with improved clinical responses has potential implications in future trials of monoclonal antibody-based therapies, and emphasizes the importance of early PK studies to optimize antibody efficacy.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalClinical Immunology
Volume154
Issue number1
DOIs
StatePublished - Sep 2014

Fingerprint

Non-Hodgkin's Lymphoma
Area Under Curve
Pharmacokinetics
Monoclonal Antibodies
Safety
Antibodies
Proxy
PRO131921 monoclonal antibody
Intravenous Infusions
Pharmaceutical Preparations
Neoplasms
Rituximab

Keywords

  • Area under the curve
  • Efficacy
  • Monoclonal antibody
  • Pharmacokinetics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL : Correlation between clinical responses and AUC pharmacokinetics. / Casulo, Carla; Vose, Julie Marie; Ho, William Y.; Kahl, Brad; Brunvand, Mark; Goy, Andre; Kasamon, Yvette; Cheson, Bruce; Friedberg, Jonathan W.

In: Clinical Immunology, Vol. 154, No. 1, 09.2014, p. 37-46.

Research output: Contribution to journalArticle

Casulo, Carla ; Vose, Julie Marie ; Ho, William Y. ; Kahl, Brad ; Brunvand, Mark ; Goy, Andre ; Kasamon, Yvette ; Cheson, Bruce ; Friedberg, Jonathan W. / A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL : Correlation between clinical responses and AUC pharmacokinetics. In: Clinical Immunology. 2014 ; Vol. 154, No. 1. pp. 37-46.
@article{9299ce7c7442462eaeab4dd455e5b2a3,
title = "A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics",
abstract = "PRO131921 is a third-generation, humanized anti-CD20 monoclonal antibody with increased antibody-dependent cytotoxicity and complement-dependent cytotoxicity compared to rituximab. In this phase I study, PRO131921 was administered as a single agent to patients with CD20+, relapsed or refractory, indolent non-Hodgkin lymphoma (NHL) who had been treated with a prior rituximab-containing regimen. The primary aim of this study was safety and tolerability of PRO131921. The secondary aim of the study, and focus of this report, was to determine the pharmacokinetics (PK) profile of PRO131921 and establish a correlation between drug exposure and clinical efficacy. Patients were treated with PRO131921 by intravenous infusion weekly for 4weeks and the dose was escalated based on safety in a 3+3 design. Twenty-four patients were treated with PRO131921 at doses from 25mg/m2 to 800mg/m2. Analysis of PK data demonstrated a correlation between higher normalized drug exposure (normalized AUC) and tumor shrinkage (p=0035). Also, normalized AUC levels were higher among responders and subjects displaying tumor shrinkage versus subjects progressing or showing no regression (p=0.030). In conclusion, PRO131921 demonstrated clinical activity in rituximab-relapsed and refractory indolent NHL patients. The observation that higher normalized AUC may be associated with improved clinical responses has potential implications in future trials of monoclonal antibody-based therapies, and emphasizes the importance of early PK studies to optimize antibody efficacy.",
keywords = "Area under the curve, Efficacy, Monoclonal antibody, Pharmacokinetics",
author = "Carla Casulo and Vose, {Julie Marie} and Ho, {William Y.} and Brad Kahl and Mark Brunvand and Andre Goy and Yvette Kasamon and Bruce Cheson and Friedberg, {Jonathan W.}",
year = "2014",
month = "9",
doi = "10.1016/j.clim.2014.06.005",
language = "English (US)",
volume = "154",
pages = "37--46",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL

T2 - Correlation between clinical responses and AUC pharmacokinetics

AU - Casulo, Carla

AU - Vose, Julie Marie

AU - Ho, William Y.

AU - Kahl, Brad

AU - Brunvand, Mark

AU - Goy, Andre

AU - Kasamon, Yvette

AU - Cheson, Bruce

AU - Friedberg, Jonathan W.

PY - 2014/9

Y1 - 2014/9

N2 - PRO131921 is a third-generation, humanized anti-CD20 monoclonal antibody with increased antibody-dependent cytotoxicity and complement-dependent cytotoxicity compared to rituximab. In this phase I study, PRO131921 was administered as a single agent to patients with CD20+, relapsed or refractory, indolent non-Hodgkin lymphoma (NHL) who had been treated with a prior rituximab-containing regimen. The primary aim of this study was safety and tolerability of PRO131921. The secondary aim of the study, and focus of this report, was to determine the pharmacokinetics (PK) profile of PRO131921 and establish a correlation between drug exposure and clinical efficacy. Patients were treated with PRO131921 by intravenous infusion weekly for 4weeks and the dose was escalated based on safety in a 3+3 design. Twenty-four patients were treated with PRO131921 at doses from 25mg/m2 to 800mg/m2. Analysis of PK data demonstrated a correlation between higher normalized drug exposure (normalized AUC) and tumor shrinkage (p=0035). Also, normalized AUC levels were higher among responders and subjects displaying tumor shrinkage versus subjects progressing or showing no regression (p=0.030). In conclusion, PRO131921 demonstrated clinical activity in rituximab-relapsed and refractory indolent NHL patients. The observation that higher normalized AUC may be associated with improved clinical responses has potential implications in future trials of monoclonal antibody-based therapies, and emphasizes the importance of early PK studies to optimize antibody efficacy.

AB - PRO131921 is a third-generation, humanized anti-CD20 monoclonal antibody with increased antibody-dependent cytotoxicity and complement-dependent cytotoxicity compared to rituximab. In this phase I study, PRO131921 was administered as a single agent to patients with CD20+, relapsed or refractory, indolent non-Hodgkin lymphoma (NHL) who had been treated with a prior rituximab-containing regimen. The primary aim of this study was safety and tolerability of PRO131921. The secondary aim of the study, and focus of this report, was to determine the pharmacokinetics (PK) profile of PRO131921 and establish a correlation between drug exposure and clinical efficacy. Patients were treated with PRO131921 by intravenous infusion weekly for 4weeks and the dose was escalated based on safety in a 3+3 design. Twenty-four patients were treated with PRO131921 at doses from 25mg/m2 to 800mg/m2. Analysis of PK data demonstrated a correlation between higher normalized drug exposure (normalized AUC) and tumor shrinkage (p=0035). Also, normalized AUC levels were higher among responders and subjects displaying tumor shrinkage versus subjects progressing or showing no regression (p=0.030). In conclusion, PRO131921 demonstrated clinical activity in rituximab-relapsed and refractory indolent NHL patients. The observation that higher normalized AUC may be associated with improved clinical responses has potential implications in future trials of monoclonal antibody-based therapies, and emphasizes the importance of early PK studies to optimize antibody efficacy.

KW - Area under the curve

KW - Efficacy

KW - Monoclonal antibody

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84903776252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903776252&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2014.06.005

DO - 10.1016/j.clim.2014.06.005

M3 - Article

C2 - 24928323

AN - SCOPUS:84903776252

VL - 154

SP - 37

EP - 46

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -